


Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application.

Listing of Claims:

1-63. (canceled)

64. (previously presented) A compound of Formula (V):



or a pharmaceutically acceptable salt, solvate, hydrate or N-oxide thereof wherein:

R^2 is $\text{C}_1\text{-C}_6$ alkyl with at least one hydrogen atom replaced by a substituent selected from the group consisting of $\text{-NR}^6\text{R}^7$, -OR^8 , $\text{-CO}_2\text{R}^9$, $\text{-S(O)}_z\text{R}^{10}$, $\text{-P(OR}^{11})\text{OR}^{12}$, aryl and substituted aryl;

R^4 is hydrogen, alkyl or substituted alkyl;

R^6 , R^7 , R^8 , R^9 , R^{10} , R^{11} and R^{12} are independently selected from the group consisting of hydrogen, acyl, substituted acyl, acyl chelate, alkyl, substituted alkyl, cycloalkyl, substituted cycloalkyl, imino and substituted imino;

R^{29} is $\text{C}_1\text{-C}_6$ alkyl with at least one hydrogen atom replaced by -NHR^{32} ;

R^{30} is acyl, substituted acyl, alkyl, substituted alkyl or a therapeutic agent;

R^{31} is hydrogen, alkyl, substituted alkyl or a therapeutic agent;

R^{32} is hydrogen, acyl, substituted acyl, alkyl, substituted alkyl or a therapeutic agent;

j and k are independently 0 or 1;


p and q are independently an integer between 0 and 100;

r and s are independently 0 or 1;


X_1 is $\text{-NH(C=C)}_g\text{CO-}$, $\text{-NH(CH}_2)_h\text{CO-}$ or $\text{-NHCH(CH}_3\text{)CO-}$;

g and h are independently 1, 2, 3, 4, 5 or 6;


X_2 is



X_3 is




X_4 is



l is an integer from 1 to 4;

X_5 is




R^{13} is hydrogen, alkyl, substituted alkyl, acyl, substituted acyl, arylalkyl, substituted arylalkyl, aryl or substituted aryl or $-S(O)_xR^{14}$;

n is an integer from 1 to 5;

x and y are independently 0, 1 or 2;

R^{14} is alkyl, substituted alkyl, acyl, substituted acyl, arylalkyl, substituted arylalkyl, aryl or substituted aryl;

X_6 is



m is an integer from 1 to 4;

X_7 is $-NH(C=CH_2)_dCO-$, $-NH(CH_2)_eCO-$ or $-NHCH(CH_3)CO-$; and

d and e are independently 1, 2, 3, 4, 5 or 6

with the proviso that at least one of R^{30} , R^{31} or R^{32} is present and is a therapeutic agent.


65. (previously presented) The compound of Claim 64, wherein

R^2 is C_1 - C_4 alkyl with at least one hydrogen atom replaced by a substituent selected from the group consisting of $-NR^6R^7$, aryl and substituted aryl;

R^4 is hydrogen;


X_1 is $-NH(CH_2)_hCO-$;

X_2 is




;

X₄ is




;

X₅ is



;

X₆ is



; and

X₇ is -NH(CH₂)_eCO-.

66. (original) The compound of Claim 65, wherein R¹³ is methyl or acetyl, s is 0, r is 0, R³⁰ is acetyl and R³¹ is a therapeutic agent.

67. (original) The compound of Claim 66, wherein the therapeutic agent is doxorubicin.

68. (previously presented) The compound of Claim 65, wherein R¹³ is methyl or hydrogen, s is 0,

r is 1, k is 1, e is 1, q is 2, R³⁰ is acetyl, R³¹ is hydrogen and R²⁹ is -(CH)₄NHR³².

69. (original) The compound of Claim 68, wherein the R³² is -CO(CH₂)₃-doxorubicin.

70. (original) The compound of Claim 68, wherein R³² is protoporphyrin.

71-74. (canceled)

75. (new) A compound of the following formula:

Ac-Pro-His-Ser-Cys(Ac)-Asn-doxorubicin.